Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TAM family comprises three homologous RTKs—TYRO3, AXL, MERTK—that regulate key processes including efferocytosis-mediated immune tolerance/inflammation resolution. Their dysregulation contributes significantly to cancer progression/immunosuppression as well as autoimmunity when absent. This makes them attractive but complex targets for therapeutic intervention across oncology/immunology fields.
Inhibition of TAM receptor tyrosine kinase activity
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TAM Receptor Family (TAM).